RedHill Biopharma Ltd.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases, infectious diseases, and oncology. The company is headquartered in Israel and operates with a U.S.-centered commercial and development focus, while its ordinary shares and ADSs are publicly traded.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved and marketed GI therapies, including Talicia for H. pylori infection.
Investigational cancer-focused assets such as opaganib and RHB-107.
Development assets targeting Crohn's disease, IBS-D, nausea, and GI intolerance.
Collaborative commercialization and development arrangements outside North America.
Customers
RedHill sells primarily into the U.S. pharmaceutical market through physicians, prescribers, and commercial channels that support prescription medicines. Its products are used by patients with gastrointestinal, infectious disease, and oncology-related conditions, while development programs are aimed at future commercialization or partnering with larger biopharma companies. The customer base therefore spans end users, healthcare providers, and licensing/commercial partners depending on product stage.
Doctors in gastroenterology and related specialties who prescribe RedHill's approved or marketed therapies.
Patients treated for H. pylori infection, IBS-D, Crohn's disease, nausea, and other GI conditions.
Pharmaceutical companies that acquire rights or share commercialization of selected products.
Hospitals, research centers, and investigators involved in company-sponsored trials.
Specialty distributors and other commercial channel participants that support product access.
Strategy
RedHill's strategy is centered on converting clinical and commercial assets into a larger gastrointestinal franchise while advancing selected development programs in infectious disease and oncology. The Talicia divestment indicates a focus on monetizing existing assets to fund new product opportunities and strengthen the commercial platform. The company is also pursuing partnered development where appropriate to broaden reach without bearing all commercialization burden itself.
A broader gastroenterology platform can create repeatable revenue and leverage existing commercial capabilities.
Late-stage programs can create future approved products and diversify revenue beyond one branded therapy.
Licensing and divestitures can supply capital while preserving upside through milestones and royalties.
Geography
RedHill is based in Israel but its operating model is centered on U.S. development and commercialization, as reflected in its business description and Nasdaq listing. The company also collaborates internationally through product partnerships and ex-North America rights arrangements, including worldwide commercialization outside North America for some assets. Geography matters because clinical development, regulatory approval, and commercial execution are split across the U.S., Israel, and selected partner markets.
Risks
RedHill faces the usual biotech risks of clinical failure, regulatory delay, and commercialization uncertainty, which are amplified by dependence on a small number of development and product assets. Partnered programs, milestone structures, and product divestitures can also make revenue and cash generation uneven from period to period. Because the company operates across the U.S., Israel, and partner markets, execution risk spans regulatory, legal, and commercial jurisdictions.
- Clinical development failureImpact: HighLikelihood: High
Pipeline value depends on positive trial outcomes for opaganib, RHB-102, RHB-204, and RHB-107.
Exposure: Pipeline assets
- Regulatory approval riskImpact: HighLikelihood: Medium
Late-stage candidates must satisfy FDA and other regulators before commercialization.
Exposure: Drug approvals
- Product concentrationImpact: HighLikelihood: Medium
Commercial performance can depend heavily on a limited number of branded products.
Exposure: Talicia and GI franchise
- Partner dependenceImpact: MediumLikelihood: Medium
Milestones and external commercialization outcomes depend on counterparties' execution.
Exposure: Apotex and Hyloris arrangements
Accounting
Judgemental itemsThe Talicia transaction includes upfront cash plus potential milestone payments, requiring careful recognition and valuation.
Impact: Can create uneven revenue or other income recognition
Clinical trial and development costs are a major expense and depend on project timing.
Impact: Affects operating results and quarter-to-quarter comparability
Drug programs and rights must be tested if expected commercial value weakens.
Impact: Could trigger non-cash write-downs
Similar listed companies
Publicly listed companies with a comparable business focus.
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Madrigal Pharmaceuticals, Inc
MDGL · Pharmaceutical Preparations
Madrigal Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on developing and selling therapies for metabolic dysfunction-associated steatohepatitis (MASH).
Rigel Pharmaceuticals, Inc
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
BioLineRx Ltd.
BLRX · Pharmaceutical Preparations
Biohit Oyj
BIOBV · Biotechnology
Biohit Oyj is a Finnish biotechnology company that operates on a global scale, focusing on the development of diagnostic products and health-promoting supplements.
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
Last updated: 28/09/2026